News

BioSpace16h
Lilly’s Mounjaro ‘Good Enough’ in Cardio Trial, Will Seek Expanded Approval
While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase III cardiovascular outcomes trial, analysts had hoped for statistical ...
Pharma major Eli Lilly claims its weight loss drug reduces cardiovascular risks in Type 2 diabetes patients
Eli Lilly's Mounjaro demonstrates significant cardiovascular benefits for Type 2 diabetes patients with heart disease, ...
Fierce Pharma19h
Lilly's Mounjaro shows its cardio benefits in Trulicity head-to-head trial
A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...
Lilly set for strong quarter after Novo profit warning
Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...
What's Going On With Eli Lilly Stock On Tuesday?
Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...
Eli Lilly and Company (LLY): We Sold Some Lilly, Says Jim Cramer
We recently published 12 Stocks Jim Cramer Recently Discussed As He Commented On A “Sea Of Green”. Eli Lilly and Company ...
Lilly's cancer drug more effective than AbbVie's in head-to-head study
Eli Lilly said on Tuesday its drug for a type of blood cancer was more effective in a head-to-head study against AbbVie's ...
Eli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.
Eli Lilly drug Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with the ...